Design Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Design Therapeutics

19/03/2024 21:02

* Design Therapeutics Inc  DSGN.OQ  reported a quarterly
adjusted
loss of 21 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -31 cents.  The mean expectation of
four analysts for the quarter was for a loss of 31 cents per
share. Wall Street expected results to range from -38 cents
to -28 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Design Therapeutics Inc's reported EPS for the quarter was
a
loss of 21 cents​.
    * The company reported a quarterly loss of $11.84 million.
    * Design Therapeutics Inc shares had fallen by 4.9% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Design
Therapeutics Inc is $4.50 
This summary was machine generated from LSEG data March 19 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.31          -0.21          Beat
 Sep. 30 2023      -0.41          -0.28          Beat
 Jun. 30 2023      -0.40          -0.36          Beat
 Mar. 31 2023      -0.36          -0.35          Beat